---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-126973"
form_type: "8-K"
ticker: "BNBX"
cik: "0000744452"
company_name: "BNB PLUS CORP."
filed_at: "2022-12-14T23:59:59+00:00"
generated_at: "2026-06-21T05:01:25.659102+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Applied DNA Sciences FY2022 revenue up 101% to $18.2M; operating loss widens to $14.0M

## Summary
- Total revenue $18.2M, +101% YoY; COVID-19 testing revenue $15.5M (85% of total).
- Q4 revenue $3.6M (+17% Q/Q, +20% YoY); gross profit margin fell to 12% from 33%.
- Operating loss $14.0M vs $13.3M; adjusted EBITDA -$9.9M.
- Cash and equivalents $15.2M; secured $12M public offering and $3.7M warrant exercise in Q4.
- Company plans cGMP capacity for linearDNA platform by end of CY2023; focuses on PGx testing and UFLP Act.

## SEC filing metadata
- accession: 0001104659-22-126973
- form_type: 8-K
- ticker: BNBX
- cik: 0000744452
- company_name: BNB PLUS CORP.
- filed_at: 2022-12-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744452/000110465922126973/0001104659-22-126973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744452/000110465922126973/tm2232660d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-126973
- JSON: https://secwatch.observer/filing/0001104659-22-126973.json
- Plain text: https://secwatch.observer/filing/0001104659-22-126973.txt

## Key facts
- Earnings Releases
  BNB PLUS CORP. reported the fiscal year ended September 30, 2022 results: revenue $18.2 million.
  - Period: the fiscal year ended September 30, 2022
  - Revenue: $18.2 million
  - Result: reported results
  source text: Total revenues increased 101% to $18.2 million, which included $15.5 million in clinical laboratory service revenues (COVID-19 test revenue).
  evidence_url: https://www.sec.gov/Archives/edgar/data/744452/000110465922126973/0001104659-22-126973-index.htm
- Earnings Releases
  BNB PLUS CORP. reported the fourth quarter ended September 30, 2022 results: revenue $3.6 million.
  - Period: the fourth quarter ended September 30, 2022
  - Revenue: $3.6 million
  - Result: reported results
  source text: Total revenues increased 17% to $3.6 million, which included $2.9 million in clinical laboratory service revenues (COVID-19 testing revenue).
  evidence_url: https://www.sec.gov/Archives/edgar/data/744452/000110465922126973/0001104659-22-126973-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.